A supervised adverse drug reaction signalling framework imitating Bradford Hill’s causality considerations  by Reps, Jenna Marie et al.
Journal of Biomedical Informatics 56 (2015) 356–368Contents lists available at ScienceDirect
Journal of Biomedical Informatics
journal homepage: www.elsevier .com/locate /y jb inA supervised adverse drug reaction signalling framework imitating
Bradford Hill’s causality considerationshttp://dx.doi.org/10.1016/j.jbi.2015.06.011
1532-0464/ 2015 Elsevier Inc. All rights reserved.
⇑ Corresponding author.
E-mail address: jenna.reps@nottingham.ac.uk (J.M. Reps).Jenna Marie Reps a,⇑, Jonathan M. Garibaldi a, Uwe Aickelin a, Jack E. Gibson b, Richard B. Hubbard b
a School of Computer Science, University of Nottingham, NG8 1BB, UK
bDivision of Epidemiology and Public Health, University of Nottingham, UK
a r t i c l e i n f o a b s t r a c tArticle history:
Received 16 March 2015
Revised 8 June 2015
Accepted 15 June 2015
Available online 24 June 2015
Keywords:
Big data
Pharmacovigilance
Longitudinal observational data
Causal effects
Signal detectionBig longitudinal observational medical data potentially hold a wealth of information and have been
recognised as potential sources for gaining new drug safety knowledge. Unfortunately there are many
complexities and underlying issues when analysing longitudinal observational data. Due to these
complexities, existing methods for large-scale detection of negative side effects using observational data
all tend to have issues distinguishing between association and causality. New methods that can better
discriminate causal and non-causal relationships need to be developed to fully utilise the data.
In this paper we propose using a set of causality considerations developed by the epidemiologist
Bradford Hill as a basis for engineering features that enable the application of supervised learning for
the problem of detecting negative side effects. The Bradford Hill considerations look at various perspec-
tives of a drug and outcome relationship to determine whether it shows causal traits. We taught a
classiﬁer to ﬁnd patterns within these perspectives and it learned to discriminate between association
and causality. The novelty of this research is the combination of supervised learning and Bradford
Hill’s causality considerations to automate the Bradford Hill’s causality assessment.
We evaluated the framework on a drug safety gold standard known as the observational medical
outcomes partnership’s non-speciﬁed association reference set. The methodology obtained excellent
discrimination ability with area under the curves ranging between 0.792 and 0.940 (existing method
optimal: 0.73) and a mean average precision of 0.640 (existing method optimal: 0.141). The proposed
features can be calculated efﬁciently and be readily updated, making the framework suitable for big
observational data.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Side effects of prescription drugs, also known as adverse drug
reactions (ADRs), occur unpredictably and present a major health-
care issue. It is possible that a generally healthy individual may
take a prescription drug for a minor problem and end up with a
potentially life threatening ADR. As a consequence, it is essential
to monitor all marketed drugs and develop methods that are cap-
able of identifying ADRs at the earliest possible point in time. The
potential beneﬁts of utilising longitudinal observational data for
detecting (also known as signalling) ADRs have been highlighted
[1]. However, unsupervised methods developed to signal ADRs
using longitudinal observational data have been found to obtain
high false positive rates consistently across data sources [2,3].
This is due to the complexities of observational data, such asmissing data and confounding, making it difﬁcult for the methods
to distinguish between association and causality. Reference sets
detailing known ADRs and non ADRs have been created to aid
the development of ADR signalling methods for longitudinal data
by enabling a fair evaluation of the methods’ ADR signalling perfor-
mances [4]. However, the creation of reference sets now presents
the opportunity of generating labelled data and developing a
supervised framework that can be applied to longitudinal observa-
tional data to signal ADRs. The success of a supervised framework
relies on identifying suitable features for discriminating between
causal and non-causal relations. The Bradford Hill causality consid-
erations are a collection of nine factors that are often considered by
experts to evaluate whether a drug and health outcome pair may
correspond to an ADR [5–7]. Therefore, the Bradford Hill causality
considerations seem an ideal basis for engineering suitable causal
discriminative features to be used as input to train an ADR sig-
nalling classiﬁer. The aim of this paper is to investigate whether
such a classiﬁer can be trained to successfully automate the
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tify causality.
Our proposed supervised Bradford Hill’s methodology is evalu-
ated by considering the problem of signalling ADRs that occur
shortly after being prescribed a medication. The data used in this
study are from a large UK electronic healthcare database that con-
tainsmedical records formillions of patients in theUK. The database
is over 300 GB in size, therefore it is important to consider the efﬁ-
ciency of the feature engineering. The Bradford Hill’s causality con-
siderations were developed by an epidemiologist in the 1960s with
experience in identifying causal relationships between drugs and
health outcomes. They have been successfully implemented, by
the process of manual review, as a means to determine causality
in many epidemiological studies [8]. The considerations state that
nine factors shouldbe consideredwhen assessing causality between
a drug and health outcome. The factors are: (i) association strength,
(ii) temporality, (iii) consistency, (iv) speciﬁcity, (v) biological gradi-
ent, (vi) experimentation, (vii) analogy, (viii) coherence and (ix)
plausibility. As longitudinal observational databases contain data
that can give insight into many of these considerations, we should
take advantage of the data available to create a supervised signal
detection framework that can imitate the causality review process.
The problem of identifying ADRs has often relied on the use of
spontaneous reporting system (SRS) data. SRS data are composed
of reported cases where somebody has suspected that a drug
caused an ADR [9]. Common methods for detecting ADRs using
SRS data are the disproportionality methods [10] that calculate a
measure of association strength between the drug and health out-
come based on inferring approximate background rates using all
the reports. However, it is not possible to calculate the actual back-
ground incidence rates corresponding to the drug or health out-
come using SRS data. Issues with under-reporting [11] can limit
the ability to detect ADRs using SRS data and consequently, there
has been an interest in using longitudinal observational data to
aid ADR detection. Recent advances in using SRS data for signalling
ADRs have focused on utilising all the SRS data and have consid-
ered non-association strength features [12,13]. It was shown that
considering a variety of features lead to an improvement in ADR
detection compared to standard methods [12]. However, this idea
is currently unexplored for ADR detection using longitudinal
observational databases, although there has been preliminary
work suggesting Bradford Hill based features may add a new per-
spective for analysing electronic healthcare records [14].
Longitudinal observational data has been a recent focus of
attention for extracting new drug safety knowledge due to it being
a cheaper and often safer alternative to experimentation such as
randomised controlled trials. Existing method for signalling ADRs
using longitudinal observational databases include adapted dispro-
portionality methods [15,16], association rule mining techniques
[17,18], or adaptions of epidemiological studies [19]. All the large
scale signalling methods are unsupervised, focus mostly on the
measure of association strength and tend to have a high false
positive rate in real life data [2,3], although some supervised
techniques have been developed for speciﬁc cases. In [20], an
ensemble technique combining simple epidemiology study designs
to identify paediatric ADRs was shown to perform well. This sug-
gested that incorporating supervised learning for ADR detection
might lead to the improvement of signalling ADRs. For supervised
learning to be fully utilised in this ﬁeld, it is important to identify
suitable features for the model. This motivates the idea of using a
standard set of causal considerations widely implemented by
experts in the ﬁeld of epidemiology as a basis to engineer features.
Numerous observational databases, including electronic healthcare
records, tend to have hierarchies in the data recording [21,22].
It may be important to consider the hierarchies when searching
for causal relationships because the relationship may benon-obvious when considering a high level item due to it occurring
less frequently, but obvious when an abstract perspective is taken.
If not taken into consideration, the hierarchal nature of the data-
bases may weaken a signal. Therefore, we also propose features
based on medical event coding hierarchies.
Outside of the ﬁeld of drug safety, existing methods developed
with the aim of identifying causal relationships within longitudinal
observational data are often based on Bayesian networks [23]. Due
to the complexity of creating a complete Bayesian network, many
of the proposed methods are considered inappropriate for ‘big’
data [24]. However, constraint-based causal detection has been
suggested as a means to handle ‘big’ data by applying metaheuris-
tics that reduce the problem space [25]. Unfortunately these meth-
ods cannot overcome the common issues found within medical
longitudinal data such as selection bias and do not consider
hierarchal structures, and are therefore not currently suitable for
signalling ADRs.
The continuation of this paper is as follows. Section 2 details the
database used within this research and the proposed supervised
Bradford Hill framework. In Section 3 we present the results of
the supervised Bradford Hill framework’s performance for sig-
nalling ADRs using a real database containing millions of UK
patient records. The implications of the results are discussed in
Section 4. The paper concludes with Section 5.
2. Materials and methods
2.1. THIN database
The data used in this paper were extracted from The Health
Improvement Network (THIN) database, an electronic healthcare
database containing UK primary care records for over 3.7 million
active patients [26] (www.thin-uk.com). As the database contains
time stamped records of medical events (e.g., myocardial infarction
or vomiting) and drug prescriptions, each patient’s medical state
can be observed over time and temporal relationships between
drugs and medical events can be identiﬁed. The THIN data used
in this research contained over 200 million medical records and
over 350 million prescription records.
The THIN database consists of heterogeneous data withmultiple
hierarchal structures. The database contains three key tables; the
patient table, the medical table and the therapy table. For privacy
reasons the patients’ identities are not stored in the database,
instead, each patient is assigned a unique reference known as the
patientID that is used to determine which patient each record in
the database corresponds to. The patient table contains information
about each patient such as their date of birth, gender and date of
registration or date of death (if they have died). The medical and
therapy tables contain time stamped records of anymedical or ther-
apy event experienced by the patients, respectively. The database is
normalised such that medical event descriptions and drug details
are stored into separate tables and linked with unique references.
The unique reference of a medical event is known as the Read code
[22] and the unique reference of a drug is known as a drugcode.
The Read codes have a hierarchical coding system encompass-
ing ﬁve levels of speciﬁcity, with level one Read codes representing
very general events and level ﬁve Read codes representing very
speciﬁc events. The level of a Read code is determined by its length.
An example of a level one Read code is ‘1’ and an example of a level
5 Read code is ‘11a1b’. The level 1 Read code ‘G’ is the parent of any
Read code starting with ‘G’. For example, the level 1 Read code ‘G’
representing the medical event ‘Circulatory system disease’, it is
the parent of the Read codes:
Level 2 : ‘G5’ – ‘Other forms of heart disease’.
Level 3 : ‘G57’ – ‘Cardiac dysrhythmias’.
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Level 5 : ‘G57y1’ – ‘Severe sinus bradycardia’.
We deﬁne an equivalence relationship between Read codes as,
ReadcodemkReadcoden if the level k parent of Readcodem is the
same as the level k parent of Readcoden. For example,
G512G5724. Prescription drugs are recorded via a drugcode and
have an associated British National Formula (BNF) code [27].
The BNF code also has a hierarchal structure and can be used to
identify similar drugs. In the THIN database there are more than
66,000 drugcodes and 100,000 Read codes.
2.1.1. THIN processing
Care needs to be taken with newly registered patients as
patients can move to new general practices at any point in their life
and may have existing medical conditions that get recorded when
they join the new practice. Newly registered patients have the
potential to bias results as doctors may record medical events that
are pre-existing, but these events will have an incorrect times-
tamp. It has been shown that the probability of pre-existing
medical events being recorded into the THIN database for newly(a) S
(b) Flo
Fig. 1. The overall ﬂowchartregistered patients is signiﬁcantly reduced after a year of the
patient being registered [28]. Consequently, to prevent newly reg-
istered patients biasing results, the ﬁrst year after registration is
ignored in this study. We also ignore drug prescription records that
occurred within the ﬁnal month of the latest THIN data collection
date as including these might cause under-reporting.2.2. Supervised ADR signalling framework
The supervised ADR framework (SADR) involves three steps.
Fig. 1 presents the ﬂowchart of the framework, showing how the
framework is used to signal new ADRs once a classiﬁer is trained.
The ﬁrst step is to extract the dataset based on existing reference
sets developed for evaluating signal detection methods for longitu-
dinal observational data [29]. This step involves identifying the
drug-health outcome pairs and their label (e.g., is the drug a known
ADR or non-ADR of the health outcome?). The second step of the
SADR framework is to implement feature engineering to combine
existing drug safety measure features and create novel features
that cover the Bradford Hill strength, temporality, speciﬁcity,
experimentation and biological gradient considerations. The otherteps
wchart
of the SADR framework.
Table 1
Mapping between OMOP drugs and BNF codes used to map OMOP drugs to THIN
drugs.
Drug BNF Count
HOI Read
OMOP ACE inhibitor 02.05.05.01 527 566
OMOP antibiotics 05.01.08.00 292 301
OMOP antibiotics 05.01.03.00 232 243
OMOP antibiotics 05.01.05.00 299 315
OMOP antiepileptics 04.08.01.00 417 440
OMOP benzodiazepines 04.01.02.00 345 371
OMOP benzodiazepines 04.08.02.00 6 6
OMOP beta blockers 02.04.00.00 499 528
OMOP bisphosphonates 06.06.02.00 282 301
OMOP tricyclic antidepressants 04.03.01.00 443 478
OMOP typical antipsychotics 04.02.01.00 307 332
OMOP typical antipsychotics 04.06.00.00 7 7
OMOP typical antipsychotics 23.00.00.00 1 1
OMOP warfarin 02.08.02.00 327 345
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erally being available in a single longitudinal observational data-
base. Features speciﬁc to the hierarchal structures of medical
event codings are also proposed. The third step is training a binary
classiﬁer using the reference set labels and Bradford Hill consider-
ation based features to produce a supervised ADR signal detection
model that can discriminate between causality and association. To
evaluate the suitability of the various features, the classiﬁer is
trained on a subset of the labelled data and is validated on the
remaining subset of the labelled data to investigate the agreement
between the prediction and truth and ensure the classiﬁer is
generalizable (i.e., should perform as well on new data). Due to
limited deﬁnitive knowledge of known ADRs and non-ADRs, this
is the best approach to determine the performance of the classiﬁer
for signalling ADRs. In this paper we use the random forest binary
classiﬁer as this was shown to perform well for the THIN data in
previous work [20] and this was also supported by preliminary
results.
The SADR framework is only applied to drug and Read code
pairs where the Read code occurred for 3 or more patients within
the month of the drug prescription. This restriction is due to this
paper focusing on ADRs that occur shortly after the drug is
ingested, so a month period is a trade off between ensuring the
ADR is recorded while reducing the amount of noise. If the Read
code occurs for less than 3 patients within the month after the drug
then it would be very difﬁcult to statistically show the correspond-
ing medical event is an ADR and the three or more limit is a
common threshold applied in pharmacovigilance [30].2.2.1. Step 1: Create Dataset
The observational medical outcomes partnership (OMOP) have
provided a non-speciﬁed association (NSA) reference set contain-
ing drug-health outcome of interest (HOI) pairs known to
correspond to ADRs or non-ADRs [29]. This reference set was gen-
erated speciﬁcally for evaluating signal generating methods to
enable a fair comparison. This set states whether the HOI occurs
shortly after drug exposure, or after long term exposure.
Matching the OMOP NSA reference set with the THIN data
caused some issues. THIN record their prescriptions using a unique
drug coding system (a transformation of the multilex code) and
there is currently no way to map the THIN prescription coding to
the OMOP reference set coding without requiring extensive man-
ual work from the THIN staff. To overcome this issue we managed
to identify suitable BNF codes for the OMOP drugs and used the
BNF as a way to match the OMOP drug and the THIN drugcodes.
There is a mapping between the THIN Read codes and the OMOP
health outcome codes, however this is not one-to-one as the
Read clinical coding suffers from redundancy. Consequently, it
was common to have multiple drug-Read code pairs for each
drug-HOI pair.
There were issues ﬁnding a suitable BNF code for Amphotericin.
We could not ﬁnd any prescriptions of drugs with the BNF code
05020300 (Amphotericin) in the THIN data as Amphotericin was
recorded with the BNF codes 05020000, 13100200 or 12030200
but these also corresponded to non-Amphotericin drugs.
Therefore we excluded Amphotericin from the analysis. Table 1
shows the BNF mappings of the drugs used and the number of
HOI or Read codes paired with each drug in the dataset. It can be
seen there were multiple Read codes for each HOI. As the perfor-
mance of a classiﬁer is likely to improve with a larger training
set, we decided to keep the drug-Read code pairs rather than
aggregating them into drug-HOI pairs, although this does means
some of the signals may be weaker.
At this point we had a list of 4249 drug-Read code pairs,
drugi  Readcodej, and their ground truth labels (e.g., whether thepair is a known ADR or non-ADR). The next step was to generate
suitable features for each pair.2.2.2. Step 2: Features Engineering
Features based on the ﬁve factors of the Bradford Hill consider-
ations and speciﬁc to the hierarchal medical event coding struc-
tures were calculated per drug-Read code pair. A summary of
these features can be found in Table A.7 within Appendix A. A total
of 17 different features were proposed based on the Bradford Hill
considerations and another 10 are proposed based on hierarchical
structures. For some of the factors we considered numerous similar
features that may be correlated as this is the ﬁrst extensive study
combining features based on the Bradford Hill considerations and
it is not known which features may be more suitable. We investi-
gated the importance of the features based on the average total
decrease in Gini impurity gained by splitting the tree’s node on a
particular feature within the random forest (the importance func-
tion in the R randomForest library) [31].
The data used to generate the features includes the unique ID of
the patient, the patient’s age, the patient’s gender, the dosage of
the drug and a value indicating how noisy the data point may be
due to how many other drugs the patient was prescribed in the
month before and after the prescription. To calculate the features
we extract certain records from the THIN database,
 xi;:k ¼ ðpatientID; age; gender; dosage;noiseÞ is a vector corre-
sponding the details of the kth prescription of drugi within the
database.
 yi;:k ¼ ðpatientID; age; gender; dosage;noiseÞ is a vector corre-
sponding the details of the kth prescription of drugi within the
database but where there has been no recording of the same
drugcode within the past 13 months for the patient.
 zi;:k ¼ ðpatientID; age; gender; dosage;noiseÞ is a vector corre-
sponding the details of the kth prescription of drugi within the
database but where there has been no recording of any drug
from the same drug family within the past 13 months for the
patient.
The age is the patient’s age when prescribed the drug, the gen-
der is 1 if male and 0 otherwise and the dosage is the dosage of the
prescription. The noise value corresponds to the number of other
drugcodes that are prescribed for the same patient within 30 days
before and 30 days after the drug prescription of interest. The
instances when a patient experiences a medical event (Readcodej)
within a hazard period centred on the drug (drugi) are,
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vector corresponding the details of the kth time Readcodej is
recorded between u and v days after the drugi is recorded
within the database.
 y½u;v ;i;jk ¼ ðpatientID; age; gender; dosage;noise; first3; first4Þ is a
vector corresponding the details of the kth time Readcodej is
recorded between u and v days after drugi is recorded for the
ﬁrst time in 13 months for the patient within the database.
 z½u;v ;i;jk ¼ ðpatientID; age; gender; dosage;noise; first3; first4Þ is a
vector corresponding the details of the kth time Readcodej is
recorded between u and v days after the drugi is recorded and
no drug from the same drug family is recorded for the patient
within the previous 13 months within the database.
In the above vectors the ﬁrst ﬁve elements correspond to the
same details as the prescription vector but the binary element
ﬁrst3 is 1 iff there are no previous recordings of any
Readcode3 Readcodej for the patient and ﬁrst4 is 1 iff there are
no previous recordings of any Readcode4 Readcodej for the
patient.
We deﬁne Xi;: ¼ fxi;:1 ; . . . ;xi;:mg to be the set of all vectors detailing
each prescription of drugi, so jXi;:j is the total number of prescrip-
tions of drugi. Y
i;: and Zi;: are similarly used to denote the set of vec-
tors detailing each prescription of drugi such that the drug has not
been prescribed within the previous 13 months or a similar drug
has not been recorded within the previous 13 months respectively.
We deﬁne X½u;v ;i;j ¼ fx½u;v ;i;j1 ; . . . ;x½u;v ;i;jm g, so the cardinality of X½u;v ;i;j
(denoted jX ½u;v ;i;jj) corresponds to the number of prescription of
drugi that have the Readcodej recorded within their ½u;v  hazard
period. Similarly, Y ½u;v ;i;j ¼ fy½u;v ;i;j1 ; . . . ; y½u;v ;i;jm g and
Z½u;v ;i;j ¼ fz½u;v ;i;j1 ; . . . ; z½u;v ;i;jm g.
The proposed features are,
(i) Strength – This factor represents the association strength, as
generally a causal relationship is likely to have a large value
of association, so a higher association means a higher likeli-
hood of a causal relationship. A common way to calculate
the association strength for drug safety (which could also
be applied in general) is by investigating variation in the risk
of experiencing a health outcome in patients exposed to a
drug (or antecedent) and those unexposed.
The risk of Readcodej during a deﬁned time period after drugi
for a speciﬁc set of THIN records is simply the number of
prescriptions of drugi in the set where Readcodej was
recorded within a deﬁned time period after drugi divided
by the total number of prescriptions of drugi in the set.
Similarly, the risk of Readcodej during a deﬁned time period
after any drug other than drugi for a speciﬁc set of THIN
records is the number of prescriptions of any non-drugi drug
in the set where Readcodej was recorded within the deﬁned
time period afterwards divided by the total number of pre-
scriptions of any non-drugi drug in the set.
The risk difference is the risk of the health outcome in the
group of patients exposed to the drug minus the risk of the
health outcome in some control group of patients. The risk
difference used in this study is the risk of Readcodej during
the 1–30 day period after drugi minus the risk of the
Readcodej during the 1–30 day period after any other drug.
The 1–30 day period was chosen as we are interested in
acutely occurring ADRs, but this period could be adjusted
to signal ADRs that take longer to occur. The formal calcula-
tions for the different set of THIN records X, Y and Z are,Attri;j1 ¼ X½1;30;i;j
  .jXi;:j X
s–i
jX½1;30;s;jj
,X
s–i
jXs;:j
 !
Attri;j2 ¼ Y ½1;30;i;j
  .jYi;:j X
s–i
jY ½1;30;s;jj
,X
s–i
jYs;:j
 !
Attri;j3 ¼ Z½1;30;i;j
  .jZi;:j X
s–i
jZ½1;30;s;jj
,X
s–i
jZs;:j
 !
ð1Þ(ii) Speciﬁcity – The speciﬁcity factor has been interpreted in
many ways. The original interpretation is that it investigates
whether the drug is observed to cause one or many medical
events. There has been a debate regarding this consideration
as some researchers believe it to be generally uninformative
[32]. However, it has been argued that it can have a use for
identifying causal relationships [33]. Some researchers con-
sider the speciﬁcity to correspond to how speciﬁc the rela-
tionship is, for example is the association mainly found in
a certain age and gender subpopulation or is the drug asso-
ciated to a very speciﬁc medical event? One way to easily
calculate whether the association tends to occur for a speci-
ﬁc age range is to calculate the average age of the patients
experiencing the medical event within the 1–30 day period
after the drug and compare this to the average age of all
the patients prescribed the drug,Attri;j4 ¼ m
Xn
k¼1
x½1;30;i;jk2
 !,
n
Xm
k¼1
xi;:k2
 !
Attri;j5 ¼ m
Xn
k¼1
y½1;30;i;jk2
 !,
n
Xm
k¼1
yi;:k2
 !
Attri;j6 ¼ m
Xn
k¼1
z½1;30;i;jk2
 !,
n
Xm
k¼1
zi;:k2
 !
ð2Þ
Another speciﬁcity consideration is whether the association
occurs more for one speciﬁc gender, an easy way to calculate
a measure for this is to compare the fraction of patient that
experience the medical event within the 1–30 day period
after the drug who are male divided by the fraction of
patients that are prescribed the drug who are male,
Attri;j7 ¼ m
Xn
k¼1
x½1;30;i;jk3
 !,
n
Xm
k¼1
xi;:k3
 !
Attri;j8 ¼ m
Xn
k¼1
y½1;30;i;jk3
 !,
n
Xm
k¼1
yi;:k3
 !
Attri;j9 ¼ m
Xn
k¼1
z½1;30;i;jk3
 !,
n
Xm
k¼1
zi;:k3
 !
ð3Þ
and the ﬁnal speciﬁcity feature is how speciﬁc the medical
event is, which can be determined by the level of the Read
code. We create a feature indicating whether the Read code
is a level 5, level 4, level 3 or level 2 Read code,
Attri;j10 ¼
5 if Readcodej is a level 5 Read code
4 if Readcodej is a level 4 Read code
3 if Readcodej is a level 3 Read code
2 if Readcodej is a level 2 Read code
1 otherwise
8>>>><
>>>>:
ð4Þ(iii) Temporality – This factor investigates the direction of the
relationship. If the relationship is causal then the drug must
occur before the medical event. In [34], the authors used
temporality features to train a classiﬁer to discriminate
between indicators and adverse events. This has also been
seen in [35], where the authors used the temporality
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tor we consider how often Readcodej occurs during the 1–
30 day period after a prescription of drugi compared to the
1 to 30 day period before drugi,Attri;j11 ¼ X½1;30;i;j
 . X½30;1;i;j 
Attri;j12 ¼ Y ½1;30;i;j
 . Y ½30;1;i;j 
Attri;j13 ¼ Z½1;30;i;j
 . Z½30;1;i;j 
ð5Þ(iv) Biological gradient – In the context of detecting ADRs this
relates to the dosage of the drug. It is generally the case,
but not always [36], that there is a monotonic increasing
relationship between the dosage of the drug and the proba-
bility of experiencing the ADR [37]. Due to this, Bradford
Hill’s considerations suggest that the dosage should be con-
sidered when determining causality, as medical events that
occur more with high dosages are more likely to correspond
to ADRs. A simple and efﬁcient feature of the biological gra-
dient criterion is to compare the average dosage given to
patients who experienced the medical event within a month
of taking the drug divided by the average dosage of the
patients prescribed the drug,Attri;j14 ¼ m
Xn
k¼1
x½1;30;i;jk4
 !,
n
Xm
k¼1
xi;:k4
 !
ð6Þ
Attri;j15 ¼ m
Xn
k¼1
y½1;30;i;jk4
 !,
n
Xm
k¼1
yi;:k4
 !
ð7Þ
Attri;j16 ¼ m
Xn
k¼1
z½1;30;i;jk4
 !,
n
Xm
k¼1
zi;:k4
 !
ð8Þ
It could be possible to generate an improved feature of the
biological gradient by investigating the correlation between
the time to the health outcome and the dosage.
Unfortunately this would be inefﬁcient when analysing hun-
dreds or thousands of drug and health outcome pairs, so the
comparison of the averages were chosen instead.(v) Experimentation – This has been openly interpreted. Some
people believe this factor refers to using results of experi-
ments, such as clinical trials, while others consider it to
correspond to investigating the outcome fromwhen a patient
has a repeat of the antecedent event [36]. For the latter, in the
context of ADRs, it is clear that when a patient experiences an
ADR it will occur every time after the drug is ingested (under
the same conditions) but should not be present when the
drug stops being ingested. Therefore, if the drug is prescribed
two or more distinct times (break of 13 months or more
between prescriptions) for a patient and the medical event
always follows but stops when the drug stops, then this
would be strong evidence to suggest a causal relationship.
Therefore, we calculate the number of people who
experience Readcodej within a 1–30 day period after drugi
for two or more distinct prescriptions and never during the
1–30 day period before divided by the number of patients
who have two or more distinct prescriptions,Attri;j17 ¼
y½1;30;i;jk1
y½1;30;i;jk1 2 [s–ky½1;30;i;js1
 
\ [
s
y½30;1;i;js1
 c 

yi;k1
yi;k1 2 [s–kyi;s1
 

ð9Þ(vi) Hierarchical speciﬁc – We also propose features for dealing
with the hierarchical medical event coding structures foundwithin THIN (and also in many other medical databases).
The ﬁrst feature is related to the noise caused by patients
taking multiple prescriptions. If a patient is taking more than
one drug then the medical event may be caused by the other
drug, so the more drugs a patient is taking the higher the risk
of confounding due to other drugs. The noise value in the
prescription vector tells us how many others drugs the
patient has taken around the prescription, so we calculate
the average number of other drugs recorded within the 1–
30 day period before or after drugi for the patients experi-
encing Readcodej divided by the average over all prescrip-
tions of drugi,
Xn !, Xm !
Attri;j18 ¼ m
k¼1
x½1;30;i;jk5 n
k¼1
xi;:k5 ð10Þ
Attri;j19 ¼ m
Xn
k¼1
y½1;30;i;jk5
 !,
n
Xm
k¼1
yi;:k5
 !
ð11Þ
Attri;j20 ¼ m
Xn
k¼1
z½1;30;i;jk5
 !,
n
Xm
k¼1
zi;:k5
 !
ð12ÞTo deal with the hierarchical structures we also generate features
that can give insight into when the association might correspond
to a medical event that has previously been recorded but as a more
general Read code. Firstly we calculate the number of times the
level 3 version of Readcodej is recorded for the ﬁrst time ever within
a 1–30 day period after drugi divided by the number of times the
level 4 version of Readcodej is recorded for the ﬁrst time within
the 1–30 day period after drugi,
Attri;j21 ¼
Xn
p¼1
x½1;30;i;jp6
,Xn
p¼1
x½1;30;i;jp7 ð13Þ
The ﬁnal two features consider the temporality measure but when
considering more general versions of the Read code. These features
calculate similar values to those used in the temporality section but
when reducing all the Read codes to their level 4 versions or level 3
versions respectively,
Attri;j22 ¼
[
fkjk4 jg
X ½1;30;i;k


, [
fkjk4jg
X½30;1;i;k

 ð14Þ
Attri;j23 ¼
[
fkjk3 jg
X ½1;30;i;k


, [
fkjk3jg
X½30;1;i;k

 ð15Þ
Attri;j24 ¼
[
fkjk4 jg
Y ½1;30;i;k


, [
fkjk4jg
Y ½30;1;i;k

 ð16Þ
Attri;j25 ¼
[
fkjk3 jg
Y ½1;30;i;k


, [
fkjk3jg
Y ½30;1;i;k

 ð17Þ
Attri;j26 ¼
[
fkjk4 jg
Z½1;30;i;k


, [
fkjk4jg
Z½30;1;i;k

 ð18Þ
Attri;j27 ¼
[
fkjk3 jg
Z½1;30;i;k


, [
fkjk3jg
Z½30;1;i;k

 ð19Þ
After calculating the features for each drugi  Readcodej pair we
have the corresponding feature vector Attri;j 2 R27Attri;j ¼
ðAttri;j1 ;Attri;j2 ; . . . ;Attri;j27Þ. The Bradford Hill consideration features
are Attri;j 2 R17; Attri;j ¼ ðAttri;j1 ;Attri;j2 ; . . . ;Attri;j17Þ. The hierarchal
knowledge features are Attri;j 2 R10; Attri;j ¼ ðAttri;j18;Attri;j26; . . . ;
Attri;j27Þ. The association strength features are Attri;j 2 R3; Attri;j ¼
ðAttri;j1 ;Attri;j2 ;Attri;j3 Þ.
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30 day period after the drug. This was due to our problem focuss-
ing on signalling ADRs that occur within 30 days of the drug pre-
scription. For signalling ADRs that occur over a larger time
period, the proposed features can simply be modiﬁed by adjusting
the length of the time period observed after the potential cause
was recorded from [1,30] to any time period of any length ([a; b]).
2.2.3. Step 3: Train the classiﬁer
After engineering the features for each of the drug-Read code
pairs from the OMOP NSA reference set, where the Read code
was recorded at least 3 times within 30 days after the drug in
THIN, we trained a random forest classiﬁer. To fairly evaluate the
SADR framework, we decided to measure the trained classiﬁer’s
performance on each drug separately. This was accomplished by
creating 9 training/testing sets. Each training set contained all
the data-points for 8 of the drugs and its corresponding testing
set contained all the data points for the remaining drug. If we
trained the classiﬁer on all the labelled data then it would not be
possible to validate that the classiﬁer would work on new data.
However, leaving out the labelled data for one drug during training
and then applying the trained classiﬁer on the left out drug’s data
to compare the prediction and truth is effectively mimicking the
situation of applying the classiﬁer to new data.
The software used for the classiﬁcation was R and the ‘caret’
[38] library. A parameter grid search was applied to ﬁnd the opti-
mal number of parameters to use for each decision tree in the for-
est (the mtry parameter) and 10-fold cross validation was
implemented to reduce over ﬁtting.
2.3. Evaluation method
To investigate the importance of various proposed features, we
investigate the performance of the SADR framework (training a
random forest using both the Bradford Hill consideration and
hierarchal-based features) with a random forest trained using only
the Bradford Hill consideration based features or only theTable 2
The feature subsets used for comparison to determine the usefulness of including
more Bradford Hill considerations and features related to the hierarchal structure of
the database.
Method Number of
features
Feature set name Features included
SADR 27 All features Attr1  Attr27
Comparison 1 17 Bradford Hill Attr1  Attr17
Comparison 2 10 Hierarchal Attr18  Attr27
Comparison 3 3 Association strength Attr1  Attr3
Table 3
Performance of SADR framework when trained on 8 of the drugs and tested on the remai
returned by the grid search when 10-fold cross validation is implemented.
Test set Training set and perform
Drug ADRa nADR ADR nADR mt
OMOP benzodiazepines 36 342 369 3502 5
OMOP antiepileptics 41 403 364 3441 5
OMOP ACE inhibitor 76 491 329 3353 5
OMOP bisphosphonates 44 258 361 3586 5
OMOP beta blockers 38 492 367 3352 5
OMOP warfarin 33 313 372 3531 10
OMOP typical antipsychotics 40 301 365 3543 5
OMOP tricyclic antidepressants 54 425 351 3419 5
OMOP antibiotics 43 819 362 3025 15
Overall average – – – – –
a The ADR and nADR columns indicate the number of drug-outcome pairs labelled ashierarchal features or only the association strength features.
Table 2 lists the various feature subsets investigated for compar-
ison and details the included features.
The performancemeasures we usedwere the same as in the pre-
vious study [39] using the NSA reference set to enable a compari-
son. Using the classiﬁer’s prediction and the ground truth, the
number of true positives (TP) is the number of drug-HOIs where
the classiﬁer predicts the drug-HOIs are ADRs and the ground truth
is that the drug-HOIs are ADRs. The number of false positives (FP) is
the number of drug-HOIs where the classiﬁer predicts the
drug-HOIs are ADRs and the ground truth is that the drug-HOIs
are non-ADRs. The number of false negatives (FN) is the number
of drug-HOIs where the classiﬁer predicts the drug-HOIs are
non-ADRs and the ground truth is that the drug-HOIs are ADRs.
Finally, the number of true negatives (TN) is the number of
drug-HOIs where the classiﬁer predicts the drug-HOIs are
non-ADRs and the ground truth is that the drug-HOIs are non-ADRs.
The area under the receiver operating characteristic (ROC) curve
(AUC) considers the trade off between the sensitivity of the classiﬁ-
cation and the speciﬁcity. ROC curves are drawn by plotting the sen-
sitivity (TP/(TP + FN)) against one minus the speciﬁcity (TN/
(TN + FP)) at different threshold stringencies. The AUC of the ROC
plot gives an indication of howwell the classiﬁer performs. To com-
pare the classiﬁers the DeLong’s test at a 5% signiﬁcance level [40] is
applied to the AUCs. The DeLong’s test is a nonparametric inference
that is applied to determine whether the AUC between two paired
ROC curves is signiﬁcantly different. The average precision (AP), pre-
cision at cutoff 10 (P10), false positive rate (FPR = FP/(FP + TN)) and
Recall5 (=TP/(TP + FN)) at a FPR of 5% are also calculated.3. Results
3.1. Evaluation of the SADR framework
The results are presented in Table 3. The ﬁrst three columns
detail the data used for testing, stating which drug was excluded
from the training data and how many drug-Read code pairs corre-
sponding to ADRs and non-ADRs (nADR) were in the testing set.
The next four columns detail the training set, the optimal mtry
found by tuning the random forest on the training set using
10-fold cross validation using the AUC as the performance measure
and the classiﬁer’s AUC (plus standard deviation) obtained by the
cross-validation. The ﬁnal ﬁve columns present the various mea-
sures of performance of the trained random forest on the test set
(effectively its performance on new data). Figs. 2–4 show the
ROC plots of the SADR framework.
The combination of Bradford Hill and hierarchal features used
as inputs into a random forest for signalling ADRs resulted in anning drug. The mtry is the value corresponding to the optimal training model’s mtry
ance Test set results
ry AUC (SD) AUC AP P10 FPR Recall5
0.871(0.035) 0.940 0.730 1.000 0.003 0.611
0.879(0.045) 0.792 0.442 0.700 0.007 0.439
0.877(0.030) 0.875 0.711 1.000 0.002 0.592
0.870(0.039) 0.795 0.550 0.800 0.016 0.477
0.867(0.045) 0.922 0.766 1.000 0.004 0.711
0.881(0.036) 0.863 0.704 1.000 0.000 0.606
0.874(0.039) 0.883 0.728 1.000 0.007 0.675
0.883(0.039) 0.828 0.598 1.000 0.005 0.574
0.879(0.037) 0.862 0.533 0.800 0.026 0.558
– 0.862 0.640 0.922 0.008 0.583
ADRs or non-ADRs in the test/training sets.
(a) Ace Inhibitors (b) Antibiotics
(c) Antiepileptics (d) Benzodiazepines
Fig. 2. Receiver operating characteristic curve plots for the different drug test sets. Comparison between SADR framework (all features), Comparison 1 (Bradford Hill features
only), Comparison 2 (hierarchal features only) and Comparison 3 (association strength features only).
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sets. The top 10 drug-Read code pairs ranked by the classiﬁer’s
conﬁdence of the pair belonging to the ADR class were all true
ADRs for 6 out of the 9 drug test sets. The FPR ranged between
0.000 and 0.026 at the classiﬁer’s natural threshold and at a 5%
FPR the average recall was 0.583.
3.2. Comparison of the SADR framework against random forests with
other feature sets
The SADR framework (random forest using all the Bradford Hill
and hierarchal features) had higher minimum, maximum andmean AUCs, 0.792, 0.940 and 0.862 respectively, across the 9 test
sets compared to the random forests using only the Bradford Hill
features (comparison 1), only the hierarchal features (comparison
2) or only the association strength features (comparison 3), see
Table 4. The p-values comparing the AUC of the SADR framework
with the three comparisons for each drug test set are displayed
in Table 5. The SADR framework was signiﬁcantly better than the
random forest using association strength features for all drugs
except the Tricyclic antidepressants, although this p-value
approached signiﬁcance (0.0584). The SADR framework was signif-
icantly better than the random forest using the hierarchal features
for the majority of drugs (6 out of the 9 drugs). However, the SADR
(a) Betablockers (b) Bisphosphonates
(c) Tricyclic antidepressants (d) Typical antipsychotics
Fig. 3. Receiver operating characteristic curve plots for the different drug test sets. Comparison between SADR framework (all features), Comparison 1 (Bradford Hill features
only), Comparison 2 (hierarchal features only) and Comparison 3 (association strength features only).
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using the Bradford Hill features for 4 out of the 9 drugs.
3.3. Feature importance
The importance of the features is presented in Table 6.
Interestingly the feature chosen as the most important is the
experimentation feature (68.7 importance), followed by the associ-
ation strength (44.6–47.9 importance) and the hierarchal features
based on noise or the ratio to how often the Read code level 3 ver-
sion occurs for the ﬁrst time after the drug compared to the level 4version. The highest of the speciﬁcity features is the average age of
the patients prescribed any drug that experience the Read code
divided by the average of the patients prescribed the drug. In gen-
eral, the features that considered all the drug prescriptions tended
to have a higher average Gini decrease value.
The hierarchal features investigating how many times the level
3 version of the Read code occurs 30 days after the drug compared
to 30 days before had the lowest mean Gini decrease, ranging
between 3.6 and 6. Apart from these features, all the other features
seem to be useful for the model as they had average Gini decrease
values greater than 10.
Fig. 4. Receiver operating characteristic curve plots for the Warfarin test set.
Table 4
Summary of the performances of the SADR framework compared with random forests
trained on various subsets of the features proposed in Section 2.2.2 across the 9 drug
test sets. The greatest min AUC, max AUC and average AUC obtained on the 9 drug test
sets across the four methods are highlighted in bold.
Method Feature set Min
AUC
Max
AUC
Average
AUC
SADR Bradford Hill and Hierarchal 0.792 0.940 0.862
Comparison 1 Bradford Hill 0.737 0.900 0.830
Comparison 2 Hierarchal 0.721 0.869 0.787
Comparison 3 Strength Ensemble 0.637 0.797 0.742
Table 6
The importance of the features within the random forest based on the total decrease
in Gini impurity.
Category Set Att Gini decrease
Experimentation X Attr17 68.7
Association Z Attr3 47.9
Association X Attr1 46.7
Association Y Attr2 44.6
Heirarchal X Attr18 41.7
Heirarchal X Attr21 33.2
Speciﬁcity X Attr4 29.6
Heirarchal Y Attr19 28.5
Heirarchal Z Attr20 28.4
Speciﬁcity X Attr7 25.8
Speciﬁcity Y Attr5 25.0
Speciﬁcity Z Attr6 23.0
Heirarchal X Attr22 21.4
Speciﬁcity Z Attr9 21.2
peciﬁcity Y Attr8 20.5
Temporality X Attr11 20.4
Biological Gradient X Attr14 19.7
Heirarchal Z Attr26 16.9
Biological Gradient Y Attr15 16.6
Heirarchal Y Attr24 16.5
Biological Gradient Z Attr16 16.4
Temporality Y Attr12 14.1
Temporality Z Attr13 13.2
Speciﬁcity – Attr10 11.0
Heirarchal Z Attr27 6.0
Heirarchal Y Attr25 5.0
Heirarchal X Attr23 3.6
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The results show that the SADR framework (a random forest
using feature engineering based on the Bradford Hill considera-
tions and hierarchal clinical codings) leads to the optimal classiﬁer
for discriminating between causality and association. This suggests
that using the proposed features can enable supervised learning to
be applied successfully to the problem of signalling ADRs in longi-
tudinal observational data. The SADR framework obtained an aver-
age AUC of 0.862, a MAP of 0.640, an average FPR of 0.008 and an
average recall at 5% FPR of 0.583 on the OMOP NSA reference set. In
previous studies the High throughput Screening by Indiana
University obtained the highest AUC of 0.734 [39], with MAP,Table 5
The p-values from the DeLong’s bootstrap test to compare the AUC for the paired ROC curv
cases where the SADR framework did not obtain a signiﬁcantly better AUC value.
Test set Comparison 1 (Bradford Hill)
OMOP benzodiazepines 0.0046
OMOP antiepileptics 0.8309
OMOP ACE inhibitor 0.2307
OMOP bisphosphonates 0.0010
OMOP beta blockers 0.1033
OMOP warfarin 0.0045
OMOP typical antipsychotics 0.4236
OMOP tricyclic antidepressants 0.3258
OMOP antibiotics 0.0028FPR and recall at 5% FPR scores of 0.141, 0.266 and 0.367 respec-
tively. This shows that a supervised approach made possible by
the feature engineering can lead to improved ADR signalling. The
supervised approach achieved a much lower false positive rate
meaning it is extremely unlikely to signal non-ADRs.
Although the supervised approach outperformed the unsuper-
vised methods, it may be argued that the additional complexity of
the supervised approach makes it less suitable. However, we pur-
posely suggested simple features that are quick to calculate and
do not require tuning (e.g., once you know what time period of
interest to investigate ½a; b, there are no parameters to tune when
calculating the features). Conversely, the existing unsupervised
methods are generally more complex and often have parameters
that need to be tuned for new datasets and this requires applying
the methods numerous times. It is the data extraction and calcula-
tion of association strength (such as risk) from the big longitudinal
observational data that is often the time consuming aspect of both
the unsupervised and supervised methods. Due to the simplicity of
our proposed features, the framework combining the proposed fea-
ture engineering and classiﬁcation is actually likely to be quicker
that the existing unsupervised methods. In addition, the simplicity
of the features also means that they could be calculated using dis-
tributed computing tools such as Hadoop [41]. In theory, this wouldes between the SADR framework and each comparison. The bold values correspond to
Comparison 2 (Hierarchal) Comparison 3 (Strength Ensemble)
0.0000 0.0000
0.0445 0.0025
0.0000 0.0116
0.1410 0.0000
0.0095 0.0000
0.0115 0.0129
0.0019 0.0011
0.0755 0.0584
0.1974 0.0004
366 J.M. Reps et al. / Journal of Biomedical Informatics 56 (2015) 356–368make the feature extraction scalability quasi-linear and could make
the framework suitable for many terabytes of data.
Another advantage of the simplicity of the features is that it
enables them to be updated efﬁciently with the addition of new
data. For example, if we stored the number of patients prescribed
the drug who experience the Read code within 30 days (n1) as well
as the average age of the patients prescribed the drug who experi-
ence the Read code within 30 days avAge1, when new data are
added we can simply calculate how many new occurrences of
the Read code occur within 30 days of the drug n2 and the average
ages of these avAge2 to quickly update the new values
n ¼ n1 þ n2; avAge ¼ ðn1  avAge1 þ n2  avAge2Þ=ðn1 þ n2Þ. This
means we only have to extract the features on the big data once,
and then we can update the features with the addition of small
amounts of new data.
Interestingly, the results showed that the experimentation fea-
ture seemed to be good at discriminating between causal and
non-causal relationships. It is widely accepted that randomised
controlled trials, a form of experimentation, are the best way to
identify causality. The results of this paper suggest there may be
ways to use longitudinal observational data to perform a weak
form of experimentation that is still informative. The hierarchal
feature corresponding to how many other drugs a patient has
around the time of prescription could actually be interpreted as
corresponding to the original speciﬁcity deﬁnition. If a patient is
only taking one drug, then the relationship between the drug and
health outcome is more speciﬁc. This was an inﬂuential feature
in the random forest, which suggests the original speciﬁcity deﬁni-
tion may have merit, although many have argued against its use.
In this paper we did not consider any coherence, plausibility or
consistency features. The consistency features could be generated
by using alternative data, such as spontaneous reporting system
databases, and calculating the association strength for the drug
and medical event pair within that data. The plausibility and
coherence features may be possible by using the chemical struc-
ture data, as this may indicate chemical structures that are associ-
ated to an ADR or by adding a human feedback loop where a
medical expert can identify incorrectly labelled pairs. Another pos-
sibility to engineer features for plausibility would be to implement
a crowd sourcing algorithm that can extract suspected ADRs from
online forums or medical literature.
It is worth noting that the Bradford Hill considerations are
known to be limited and are consider only as a guide for inferring
causality [42]. The Bradford Hill considerations are not deﬁnitive
criteria for causality and any limitation in discriminating between
causal and non-causal relationships using these considerations will
also likely be a limitation of the SADR framework. However,
machine learning techniques such as random forest can identify
complex patterns, ones that are unlikely to be identiﬁed byTable A.7
Summary of the features used within the SADR framework.
Feature Category Description
Attr1 Strength The fraction of patients experiencing the health outcome w
outcome within 30 days of any other drug
Attr2 Strength The fraction of patients experiencing the health outcome w
fraction of patients experiencing the health outcome withi
Attr3 Strength The fraction of patients experiencing the health outcome wit
fraction of patients experiencing the health outcome withi
Attr4 Speciﬁcity The average age of patients experiencing the health outcome w
Attr5 Speciﬁcity The average age of patients experiencing the health outcome
the average age of patients ﬁrst time prescriptions in 13 m
Attr6 Speciﬁcity The average age of patients experiencing the health outcom
divided by the average age of patients ﬁrst time prescriptiohumans, which may reduce the limitations of the considerations
compared to when they are implemented manually. Also, using
the reference sets to label the data may lead to limitations, as
the reference sets may be biased towards a certain type of ADR
(e.g., ADRs that are more obvious). In this work we did not include
positive side effects of medication, however in future work the
framework could be readily modiﬁed to include a third label corre-
sponding to positive effects of medication (it would just need med-
ical experts to provide a list of drug-health outcomes where the
drugs are known to cause the beneﬁcial health outcomes). Such a
modiﬁcation would enable us to identify potential new off-target
beneﬁts of medication.
One ﬁnal comment is that the performance of supervised learn-
ing techniques will generally improve as the number of labelled
data to train on increases. Therefore, the proposed framework is
expected to improve over time as more labelled data become
available.5. Conclusion
In this paper we proposed a novel supervised ADR signalling
framework (SADR) utilising Bradford Hill’s causality considerations
to enable the implementation of a classiﬁer that can accurately sig-
nal ADRs in big longitudinal observational databases that suffer
from confounding and have hierarchal clinical code structures.
The framework trains a random forest to discriminate between
ADRs and non-ADRs using suitable features based on the
Bradford Hill causality considerations (many of which have been
previously used to signal ADRs but never combined). The trained
random forest performed well at distinguishing between ADRs
and non-ADRs when validated on the OMOP NSA reference set
(AUC ranging between 0.792 and 0.940). The classiﬁer’s perfor-
mance was better than existing unsupervised methods’ perfor-
mances calculated in previous studies [39] highlighting the
advantages of implementing supervised learning for signalling
ADRs.
Suggested future areas of work are expanding the feature engi-
neering to include the remaining Bradford Hill causality consider-
ations (analogy, consistency, plausibility and coherence) and using
the Map-Reduce paradigm to enable the extraction of the features
in quasi-linear scalability, making this framework suitable for ter-
abytes of big healthcare data.Appendix A. Feature summaries
Table A.7.ithin 30 days of the drug minus the fraction of patients experiencing the health
ithin 30 days of any ﬁrst time prescription in 13 months of the drug minus the
n 30 days of a ﬁrst time prescription in 13 months of any other drug
hin 30 days of any ﬁrst time prescription in 13 months of a drug family minus the
n 30 days of a ﬁrst time prescription in 13 months of any other drug family
ithin 30 days of the drug divided by the average age of patients prescribed the drug
within 30 days of any ﬁrst time prescription in 13 months of the drug divided by
onths of the drug
e within 30 days of any ﬁrst time prescription in 13 months of the drug family
n in 13 months of the drug family
Table A.7 (continued)
Feature Category Description
Attr7 Speciﬁcity The fraction of patients that are male out of those experiencing the health outcome within 30 days of the drug divided by the male fraction of
patients prescribed the drug
Attr8 Speciﬁcity The fraction of patients that are male out of those experiencing the health outcome within 30 days of any ﬁrst time prescription in 13 months
of the drug divided by the fraction of patients prescriptions corresponding to the ﬁrst time prescription in 13 months of the drug where the
patient is male
Attr9 Speciﬁcity The fraction of patients that are male out of those experiencing the health outcome within 30 days of any ﬁrst time prescription in 13 months
of the drug family divided by the fraction of patients that are male out of all prescriptions corresponding to the ﬁrst time prescription in
13 months of the drug family
Attr10 Speciﬁcity The hierarchal level of the Read code (this corresponds to how speciﬁc the health outcome is)
Attr11 Temporality The number of times the heath outcome occurs within 1 and 30 days after a prescription of the drug divided by the number of times the heath
outcome occurs within 1 and 30 days before a prescription of the drug
Attr12 Temporality The number of times the heath outcome occurs within 1 and 30 days after a ﬁrst time in 13 months prescription of the drug divided by the
number of times the heath outcome occurs within 1 and 30 days before a ﬁrst time in 13 months prescription of the drug
Attr13 Temporality The number of times the heath outcome occurs within 1 and 30 days after a ﬁrst time prescription in 13 months of the drug family divided by
the number of times the heath outcome occurs within 1 and 30 days before a ﬁrst time prescription in 13 months of the drug family
Attr14 Biological
gradient
The average drug dosage given to patients experiencing the health outcome within 30 days of the drug divided by the average drug dosage
given to patients prescribed the drug
Attr15 Biological
gradient
The average drug dosage given to patients experiencing the health outcome within 30 days of any ﬁrst time prescription in 13 months of the
drug divided by the average drug dosage given to patients when considering their ﬁrst time prescription in 13 months of the drug
Attr16 Biological
gradient
The average drug dosage given to patients experiencing the health outcome within 30 days of any ﬁrst time prescription in 13 months of the
drug family divided by the average drug dosage given to patients when considering all ﬁrst time prescriptions in 13 months of the drug family
Attr17 Experimentation The number of patients who were prescribe the drug and experienced the health outcome within 1 and 30 days after on two or more distinct
time periods (with 13 months or more between consecutive prescriptions of the drug) but never experienced the health outcome within 1
and 30 days prior to any prescription of the drug divided by the number of patients with multiple distinct prescription periods (with two or
more drug prescriptions with a gap of 13 months of more between consecutive prescriptions)
Attr18 Hierarchal The average number of other drugs prescribed during the 30 days before and after the drug prescription for the prescriptions where the
patient experienced the health outcome within 1 and 30 days after the prescription divided by the average number of other drugs prescribed
during the 30 days before and after the drug prescription for all prescriptions of the drug
Attr19 Hierarchal The average number of other drugs prescribed during the 30 days before and after any ﬁrst time in 13 month prescription of the drug where
the patient experienced the health outcome within 1 and 30 days after the prescription divided by the average number of other drugs
prescribed during the 30 days before and after the drug prescription for any ﬁrst time in 13 months prescription of the drug
Attr20 Hierarchal The average number of other drugs prescribed during the 30 days before and after any ﬁrst time prescription in 13 months of the drug family
where the patient experienced the health outcome within 1 and 30 days after the prescription divided by the average number of other drugs
prescribed during the 30 days before and after the drug prescription for any ﬁrst time prescription in 13 months of the drug family
Attr21 Hierarchal The number of prescriptions where the patient has the health outcome recorded within 1 and 30 days after the drug but the patient has never
had a similar but more general version of the health outcome recorded (level 4 version read code) divided by the number of prescriptions
where the patient has the health outcome recorded within 1 and 30 days after the drug but the patient has never had a similar but even more
general version of the health outcome recorded (level 3 version read code)
Attr22 Hierarchal The number of prescriptions where the patient has the more general level 4 version of the health outcome recorded within 1 and 30 days after
the drug prescription divided by the number of prescriptions where the patient has the more general level 4 version of the health outcome
recorded within 1 and 30 days before the drug prescription
Attr23 Hierarchal The number of prescriptions where the patient has the more general level 3 version of the health outcome recorded within 1 and 30 days after
the drug prescription divided by the number of prescriptions where the patient has the more general level 3 version of the health outcome
recorded within 1 and 30 days before the drug prescription
Attr24 Hierarchal The number of prescriptions where the patient has the more general level 4 version of the health outcome recorded within 1 and 30 days after
the ﬁrst time in 13 month prescription of the drug divided by the number of prescriptions where the patient has the more general level 4
version of the health outcome recorded within 1 and 30 days before the ﬁrst time in 13 months prescription of the drug
Attr25 Hierarchal The number of prescriptions where the patient has the more general level 3 version of the health outcome recorded within 1 and 30 days after
the ﬁrst time in 13 month prescription of the drug divided by the number of prescriptions where the patient has the more general level 3
version of the health outcome recorded within 1 and 30 days before the ﬁrst time in 13 months prescription of the drug
Attr26 Hierarchal The number of prescriptions where the patient has the more general level 4 version of the health outcome recorded within 1 and 30 days after
the ﬁrst time prescription in 13 months of the drug family divided by the number of prescriptions where the patient has the more general
level 4 version of the health outcome recorded within 1 and 30 days before the ﬁrst time prescription in 13 months of the drug family
Attr27 Hierarchal The number of prescriptions where the patient has the more general level 3 version of the health outcome recorded within 1 and 30 days after
the ﬁrst time prescription in 13 months of the drug family divided by the number of prescriptions where the patient has the more general
level 3 version of the health outcome recorded within 1 and 30 days before the ﬁrst time prescription in 13 months of the drug family
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